Reuters logo
BRIEF-JCR Pharmaceuticals submits application for marketing approval of JR-051 for Fabry disease
September 29, 2017 / 7:04 AM / in 20 days

BRIEF-JCR Pharmaceuticals submits application for marketing approval of JR-051 for Fabry disease

Sept 29 (Reuters) - JCR Pharmaceuticals Co Ltd

* Says it has submitted an application for marketing approval on JR-051 (recombinant alpha-galactosidase A), an enzyme replacement therapy (ERT) for Fabry disease to Ministry of Health, Labour and Welfare

Source text in Japanese: goo.gl/4MTymu

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below